DJ Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
Arix Bioscience PLC (ARIX)
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
01-Nov-2023 / 16:30 GMT/BST
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
LONDON, 1 November 2023: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a transatlantic venture capital
company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Sorriso
Pharmaceuticals ("Sorriso"), has announced that the first subject has been dosed in the Company's Phase 1/1b clinical
program of SOR102.
SOR102 is a dual-acting oral biologic treatment targeting TNF? and IL-23(p19) that is being developed for the treatment
of inflammatory bowel disease (IBD).
This Phase 1 trial is a randomized, double-blind study consisting of three parts. Parts 1 and 2 will evaluate safety,
tolerability and pharmacokinetics (PK) of single ascending oral doses and multiple oral doses in healthy participants.
Part 3 will evaluate safety, tolerability, PK, and clinical and biological activity of multiple oral doses of SOR102 in
patients with mild to severe ulcerative colitis. The trial is expected to enrol up to 60 adult participants at sites in
the United Kingdom and Europe.
Ciara Kennedy, Ph.D. CEO at Sorriso, commented: "We are excited to initiate this first-in-human trial of SOR102 as
there remains a significant need for improved therapies for patients suffering from IBD. We believe that SOR102, which
addresses two validated targets and is designed to act locally within inflamed GI tissue, has the potential to be an
oral first-line advanced therapy, with a superior efficacy and safety profile over existing systemically administered
biologics and novel oral therapies."
Robert Lyne, CEO of Arix, added: "This landmark milestone for Sorriso's lead candidate is a very exciting next step
demonstrating the Company's translational capabilities. Sorriso is addressing an area of truly unmet need, using a
highly innovative targeting approach to give hope to people suffering with severe immune-mediated diseases such as
Crohn's disease and ulcerative colitis. We look forward to seeing SOR102 develop as it advances through the Phase 1
trial."
The full text from Sorriso's announcement is reproduced below and can be accessed on the Sorriso Pharmaceuticals
website here: www.sorrisopharma.com/news/
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology
companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help
accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this
exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Sorriso Pharmaceuticals Press Release:
Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
First-in-Human Study of Novel Oral Dual-Acting Antibody in Development for Treatment of Patients with Inflammatory
Bowel Disease
SALT LAKE CITY, UT, UNITED STATES, November 1, 2023 /EINPresswire.com/ -- Sorriso Pharmaceuticals, a biopharmaceutical
company developing novel oral antibodies in immune-mediated disease, today announced that the first subject has been
dosed in the company's Phase 1/1b clinical program of SOR102. SOR102 is a dual-acting oral biologic treatment targeting
TNF? and IL-23(p19) that is being developed for the treatment of inflammatory bowel disease (IBD).
"We are excited to initiate this first-in-human trial of SOR102 as there remains a significant need for improved
therapies for patients suffering from IBD," said Ciara Kennedy, Ph.D., chief executive officer at Sorriso. "We believe
that SOR102, which addresses two validated targets and is designed to act locally within inflamed GI tissue, has the
potential to be an oral first-line advanced therapy, with a superior efficacy and safety profile over existing
systemically administered biologics and novel oral therapies."
This Phase 1 trial is a randomized, double-blind study consisting of three parts. Parts 1 and 2 will evaluate safety,
tolerability and pharmacokinetics (PK) of single ascending oral doses and multiple oral doses in healthy participants.
Part 3 will evaluate safety, tolerability, PK, and clinical and biological activity of multiple oral doses of SOR102 in
patients with mild to severe ulcerative colitis. The trial is expected to enroll up to 60 adult participants at sites
in the United Kingdom and Europe. More information about the trial is available at www.clinicaltrials.gov, identifier
NCT06080048.
About SOR102
SOR102 simultaneously inhibits TNF? and IL-23(p19), two clinically validated drivers of IBD, providing combination
therapy locally within inflamed tissue with minimal systemic exposure. This dual targeting approach may increase
efficacy through simultaneous blockade of different mechanisms of IBD.
About Sorriso Pharmaceuticals
Sorriso Pharmaceuticals is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the
treatment of immune-mediated diseases, including Crohn's disease and ulcerative colitis. The Sorriso platform generates
potent antibodies that can be delivered orally and are designed to maintain activity throughout the human intestine.
About Sorriso Pharmaceuticals
For more information, please visit www.sorrisopharma.com
=----------------------------------------------------------------------------------------------------------------------
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCM
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 282110
EQS News ID: 1762895
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1762895&application_name=news
(END) Dow Jones Newswires
November 01, 2023 12:30 ET (16:30 GMT)
